Leukemia Clinical Trials in Texas

Showing 1001-1020 of 1,290 trials

Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)

NCT01030536

The primary objectives of this study are to determine the maximum tolerated dose (MTD) or optimal biologic dose (OBD) and safety profile of CAT-8015 in participants with relapsed or refractory advanced B-cell NHL (diffuse large B-cell lymphoma \[DLBCL\], follicular lymphoma \[FL\], mantle cell lymphoma \[MCL\]) or CLL.

Non-Hodgkin LymphomaChronic Lymphocytic Leukemia

MedImmune LLC23 participantsStarted Feb 2010

Los Angeles, California, United States • Indianapolis, Indiana, United States • Bethesda, Maryland, United States +5 more locations

COMPLETEDPhase 242 miles

Sunitinib Non Small Cell Lung Cancer Patients Over 70

NCT00864721

The purpose of this research study is to find out what effects (good and bad) sunitinib has on patients and their NSCLC.

Non Small Cell Lung Cancer

US Oncology Research63 participantsStarted Feb 2009

Ocala, Florida, United States • Ocoee, Florida, United States • Minneapolis, Minnesota, United States +10 more locations

PreviousPage 51 of 65Next

Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)

Sunitinib Non Small Cell Lung Cancer Patients Over 70

Leukemia Trials in Other Cities

A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis

A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel

Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)

Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL

AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct

Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS

Early Weight-Bearing After Lapidus Arthrodesis

Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)

Evaluation of ClearLLab Leukemia and Lymphoma Panels

Other Conditions in Texas